SI2305683T1 - Farmacevtska odmerna oblika, ki obsega oksikodon hidroklorid in manj kot 25 ppm 14-hidroksikodeinona - Google Patents

Farmacevtska odmerna oblika, ki obsega oksikodon hidroklorid in manj kot 25 ppm 14-hidroksikodeinona

Info

Publication number
SI2305683T1
SI2305683T1 SI200531950T SI200531950T SI2305683T1 SI 2305683 T1 SI2305683 T1 SI 2305683T1 SI 200531950 T SI200531950 T SI 200531950T SI 200531950 T SI200531950 T SI 200531950T SI 2305683 T1 SI2305683 T1 SI 2305683T1
Authority
SI
Slovenia
Prior art keywords
hydroxycodeinone
ppm
less
dosage form
pharmaceutical dosage
Prior art date
Application number
SI200531950T
Other languages
English (en)
Inventor
Robert Chapman
Lonn S. Rider
Qi Hong
Donald Kyle
Robert Kupper
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35124996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2305683(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of SI2305683T1 publication Critical patent/SI2305683T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200531950T 2004-03-30 2005-03-30 Farmacevtska odmerna oblika, ki obsega oksikodon hidroklorid in manj kot 25 ppm 14-hidroksikodeinona SI2305683T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60153404P 2004-08-13 2004-08-13
US62007204P 2004-10-18 2004-10-18
US64862505P 2005-01-31 2005-01-31
US65177805P 2005-02-10 2005-02-10
EP10011792.8A EP2305683B8 (en) 2004-03-30 2005-03-30 Pharmaceutical dosage form comprising oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Publications (1)

Publication Number Publication Date
SI2305683T1 true SI2305683T1 (sl) 2015-04-30

Family

ID=35124996

Family Applications (5)

Application Number Title Priority Date Filing Date
SI200532046T SI2426132T1 (sl) 2004-03-30 2005-03-30 Postopek za pripravo oksikodon hidrokloridnih sestavkov z manj kot 25 ppm 14-hidroksikodeinona
SI200532200T SI2316837T1 (sl) 2004-03-30 2005-03-30 Postopek za pripravo oksikodon hidroklorida z manj kot 25 ppm 14-hidroksikodeinona
SI200531289T SI1730151T2 (sl) 2004-03-30 2005-03-30 Postopek za pripravo oksikodon hidroklorida z manj kot 25 ppm 14-hidroksikodeinona
SI200531950T SI2305683T1 (sl) 2004-03-30 2005-03-30 Farmacevtska odmerna oblika, ki obsega oksikodon hidroklorid in manj kot 25 ppm 14-hidroksikodeinona
SI200532083A SI2319846T1 (sl) 2004-03-30 2005-03-30 Postopek za pripravo oksikodon hidroklorida z manj kot 25 ppm 14-hidroksikodeinona

Family Applications Before (3)

Application Number Title Priority Date Filing Date
SI200532046T SI2426132T1 (sl) 2004-03-30 2005-03-30 Postopek za pripravo oksikodon hidrokloridnih sestavkov z manj kot 25 ppm 14-hidroksikodeinona
SI200532200T SI2316837T1 (sl) 2004-03-30 2005-03-30 Postopek za pripravo oksikodon hidroklorida z manj kot 25 ppm 14-hidroksikodeinona
SI200531289T SI1730151T2 (sl) 2004-03-30 2005-03-30 Postopek za pripravo oksikodon hidroklorida z manj kot 25 ppm 14-hidroksikodeinona

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200532083A SI2319846T1 (sl) 2004-03-30 2005-03-30 Postopek za pripravo oksikodon hidroklorida z manj kot 25 ppm 14-hidroksikodeinona

Country Status (39)

Country Link
US (35) US7129248B2 (sl)
EP (7) EP1730151B2 (sl)
JP (8) JP4912294B2 (sl)
KR (12) KR20120106784A (sl)
CN (5) CN102127086B (sl)
AP (1) AP2232A (sl)
AR (1) AR049012A1 (sl)
AT (2) ATE501150T1 (sl)
AU (2) AU2005230826C1 (sl)
BR (1) BRPI0508758B8 (sl)
CA (3) CA2774121C (sl)
CR (2) CR8593A (sl)
CY (5) CY1111487T1 (sl)
DE (2) DE202005021371U1 (sl)
DK (6) DK2316837T3 (sl)
EA (1) EA013208B1 (sl)
EC (1) ECSP066953A (sl)
ES (6) ES2362282T5 (sl)
FI (1) FI7843U1 (sl)
HK (3) HK1098745A1 (sl)
HR (5) HRP20110425T4 (sl)
HU (3) HUE036451T2 (sl)
IL (8) IL178038A (sl)
LT (2) LT2314589T (sl)
MA (1) MA28492B1 (sl)
ME (4) ME01299B (sl)
MX (2) MX363228B (sl)
MY (3) MY143205A (sl)
NO (1) NO337669B1 (sl)
NZ (3) NZ549430A (sl)
PE (1) PE20050880A1 (sl)
PL (5) PL2426132T3 (sl)
PT (5) PT2319846T (sl)
RS (5) RS57000B1 (sl)
SG (3) SG10201406658VA (sl)
SI (5) SI2426132T1 (sl)
TW (3) TWI365880B (sl)
WO (1) WO2005097801A1 (sl)
ZA (1) ZA200607181B (sl)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI365880B (en) * 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2006094672A1 (en) * 2005-03-04 2006-09-14 Euro-Celtique S.A. Method of reducing alpha, beta unsaturated ketones in opioid compositions
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
KR20150041176A (ko) 2005-11-22 2015-04-15 콘드롤드 케미컬즈, 인크. 옥시코돈 및 다른 조성물에서 오염물질인 마이클 수용체 수준을 감소시키는 방법
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
CA2644095A1 (en) 2006-03-02 2007-09-13 Mallinckrodt Inc. Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US8134002B2 (en) * 2006-10-17 2012-03-13 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CN101652369A (zh) 2006-12-04 2010-02-17 诺拉姆科有限公司 减少羟考酮碱中杂质的方法
AU2007329453B2 (en) * 2006-12-04 2013-04-04 Noramco, Llc Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2125824T3 (pl) * 2007-03-23 2014-05-30 SpecGx LLC Ulepszony sposób wytwarzania oksymorfonu z oripawiny
MX2009010931A (es) 2007-04-16 2009-10-29 Mallinckrodt Inc Reduccion novedosa de opiaceos utilizando la reaccion de transferencia catalitica de hidrogeno.
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009223061B2 (en) * 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
NZ601200A (en) * 2008-09-18 2014-02-28 Purdue Pharma Lp Pharmaceutical dosage forms comprising poly(epsilon-caprolactone)
NZ596667A (en) * 2009-07-22 2013-09-27 Gruenenthal Chemie Hot-melt extruded controlled release dosage form
PT2456424E (pt) * 2009-07-22 2013-09-30 Gruenenthal Gmbh Forma de dosagem resistente à adulteração e estabilizada contra a oxidação
KR20120059582A (ko) * 2009-08-31 2012-06-08 데포메드 인코퍼레이티드 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물
AU2010300641B2 (en) 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2011095314A2 (en) * 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
ES2642788T3 (es) 2010-05-10 2017-11-20 Euro-Celtique S.A. Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos
ES2408343B2 (es) 2010-05-10 2014-07-17 Euro-Celtique, Sa Composiciones farmacéuticas que comprenden hidromorfona y naloxona
NZ603170A (en) 2010-05-10 2015-04-24 Euro Celtique Sa Combination of active loaded granules with additional actives
ES2666404T3 (es) 2010-06-11 2018-05-04 Rhodes Technologies Procesos catalizados por metales de transición para la preparación de compuestos de N-alilo y uso de los mismos
AU2011263416B2 (en) 2010-06-11 2014-04-10 Rhodes Technologies Process for N-dealkylation of tertiary amines
ES2659168T3 (es) 2010-07-02 2018-03-14 Johnson Matthey Public Limited Company Proceso para la síntesis y purificación de oxicodona
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
CA2808541C (en) 2010-09-02 2019-01-08 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
MX2013002377A (es) 2010-09-02 2013-04-29 Gruenenthal Gmbh Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
MX348054B (es) 2011-07-29 2017-05-25 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco.
WO2013034273A1 (en) * 2011-09-05 2013-03-14 Siegfried Ltd. Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
ES2641437T3 (es) 2011-09-16 2017-11-10 Purdue Pharma Lp Formulaciones farmacéuticas resistentes a la manipulación indebida
WO2013038268A1 (en) 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant immediate release formulations
CN104010630A (zh) 2011-12-09 2014-08-27 普渡制药公司 包含聚(ε-己内酯)和聚氧乙烯的药物剂型
AU2013225106B2 (en) 2012-02-28 2017-11-02 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
UY34651A (es) 2012-03-02 2013-09-30 Rhodes Pharmaceuticals Lp ?formas de dosificación de liberación inmediata resistentes a la manipulación, procesos para prepararlas, métodos y usos de las mismas?..
CA3120681A1 (en) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
RS57913B1 (sr) 2012-04-18 2019-01-31 Gruenenthal Gmbh Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
ES2698611T3 (es) 2012-07-12 2019-02-05 SpecGx LLC Composiciones farmacéuticas disuasorias del abuso y de liberación prolongada
JP6236447B2 (ja) * 2012-07-16 2017-11-22 ローズ テクノロジーズ 改善されたオピオイド合成方法
CN104507947B (zh) * 2012-07-16 2017-06-27 罗德科技公司 用于改进的阿片样物质合成的方法
RU2639877C2 (ru) * 2012-08-03 2017-12-25 Джонсон Мэтти Паблик Лимитед Компани Способ получения оксикодона
RU2673818C2 (ru) 2012-11-30 2018-11-30 Экьюра Фармасьютикалз, Инк. Саморегулируемое высвобождение фармацевтического ингредиента
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
WO2014130714A1 (en) * 2013-02-20 2014-08-28 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
EP3027622B8 (en) 2013-08-02 2019-06-12 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
BR112016008459B1 (pt) 2013-11-07 2023-02-07 SpecGx LLC Produção de morfinanos de 6-hidroxi sem isolamento de intermediários
KR102194174B1 (ko) 2013-11-13 2020-12-23 유로-셀티큐 에스.에이. 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
WO2015107472A1 (en) 2014-01-15 2015-07-23 Rhodes Technologies Process for improved oxymorphone synthesis
JP2017502991A (ja) 2014-01-15 2017-01-26 ローズ テクノロジーズ 改良されたオキシコドン合成のための方法
US10632113B2 (en) 2014-02-05 2020-04-28 Kashiv Biosciences, Llc Abuse-resistant drug formulations with built-in overdose protection
EP3122337A4 (en) 2014-03-26 2017-11-08 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release coated reservoir solid dosage form
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
EP3166948A1 (en) * 2014-07-09 2017-05-17 Rhodes Technologies Inc. Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (zh) * 2014-12-15 2017-11-24 北大方正集团有限公司 Delta‑7溴甲纳曲酮的制备方法
US9918979B2 (en) * 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2018055199A1 (en) 2016-09-26 2018-03-29 Euro-Celtique S.A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3642207B1 (en) * 2017-06-20 2022-08-31 Johnson Matthey Public Limited Company Hydrogenation process for preparing oxycodone hydrochloride from 14-hydroxycodeinone
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113009060B (zh) * 2021-02-24 2022-10-21 西南药业股份有限公司 高效液相色谱法测定盐酸羟考酮含量的方法

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1485673A (en) 1924-03-04 Ministrator
US1468805A (en) 1923-09-25 Htabtin ereund
US420098A (en) * 1890-01-28 Mowing-machine
DE296916C (sl) *
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
DE286431C (sl)
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (ru) 1944-01-26 1944-11-30 А.И. Лютенберг Способ получени сол нокислого дигидрооксикодеинона
ES212554A1 (es) 1953-12-01 1954-08-16 Casanovas Albajes Cesar Un procedimiento para la obtención de un vidrio orgánico
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (sl) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (sl) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4272540A (en) 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US4639520A (en) 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
US4810669A (en) * 1987-07-07 1989-03-07 Oki Electric Industry Co., Ltd. Method of fabricating a semiconductor device
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (ja) * 1996-01-26 2003-08-04 株式会社デンソー 集積化半導体歪みセンサ及びその製造方法
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Procedimiento de obtencion de 14-hidroximofinonas mediante fotooxidac ion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
GB9713703D0 (en) * 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
EP1121234B1 (en) * 1998-10-14 2003-10-01 Gyros AB A matrix and method of producing said matrix
US6177567B1 (en) 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
HU229705B1 (en) * 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
AU2001258825A1 (en) 2000-05-29 2001-12-11 Shionogi And Co., Ltd. Method for labeling with tritium
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
EP1709957A3 (en) * 2001-06-05 2007-02-14 Control Delivery Systems Sustained-release analgesic compounds
JP2004534056A (ja) 2001-06-08 2004-11-11 エンドー ファーマシューティカルズ， インコーポレイティド アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
DE60230632D1 (de) 2001-07-18 2009-02-12 Euro Celtique Sa Pharmazeutische kombinationen von oxycodon und naloxon
EP1474198B1 (en) * 2002-01-15 2015-12-30 Novartis AG System for clearing aerosols from the effective anatomic dead space
ES2327034T3 (es) * 2002-03-26 2009-10-23 Euro-Celtique S.A. Composiciones recubiertas con gel de liberacion sostenida.
NZ536252A (en) 2002-04-29 2007-06-29 Alza Corp Methods and dosage forms for controlled delivery of oxycodone
US7702280B2 (en) * 2002-05-27 2010-04-20 Ntt Docomo, Inc. Mobile communication system, transmission station, reception station, relay station, communication path deciding method, and communication path deciding program
AU2003245345A1 (en) 2002-05-31 2003-12-19 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
JP4694207B2 (ja) * 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
CN100439373C (zh) * 2002-08-15 2008-12-03 诺拉姆科有限公司 羟考酮盐酸盐多晶型物
EP1603593A4 (en) 2002-11-15 2007-08-01 Branded Products For The Futur PHARMACEUTICAL COMPOSITION
MXPA05005781A (es) * 2002-11-29 2005-12-12 Forest Laboratories Combinacion de ibuprofeno y oxicodona para alivio de dolor agudo.
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
DE602004024963D1 (de) 2003-03-13 2010-02-25 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
US20070172958A1 (en) * 2004-03-30 2007-07-26 Euro-Celtique S.A. Methods for detecting 14-hydroxy codeinone and codeinone
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
WO2006004672A1 (en) 2004-06-25 2006-01-12 Tessera, Inc. Components with posts and pads
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
WO2006094672A1 (en) 2005-03-04 2006-09-14 Euro-Celtique S.A. Method of reducing alpha, beta unsaturated ketones in opioid compositions
EP1893616B1 (en) 2005-06-16 2010-12-29 Mallinckrodt, Inc. A synthetic route to 14-hydroxyl opiates through 1-halo-thebaine or analogs
KR20150041176A (ko) 2005-11-22 2015-04-15 콘드롤드 케미컬즈, 인크. 옥시코돈 및 다른 조성물에서 오염물질인 마이클 수용체 수준을 감소시키는 방법
US20070117826A1 (en) 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
CA2644095A1 (en) 2006-03-02 2007-09-13 Mallinckrodt Inc. Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
AU2007329453B2 (en) * 2006-12-04 2013-04-04 Noramco, Llc Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
CN101652369A (zh) 2006-12-04 2010-02-17 诺拉姆科有限公司 减少羟考酮碱中杂质的方法
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
ES2659168T3 (es) 2010-07-02 2018-03-14 Johnson Matthey Public Limited Company Proceso para la síntesis y purificación de oxicodona
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Also Published As

Publication number Publication date
US20160175298A1 (en) 2016-06-23
IL214050A (en) 2013-09-30
PL1730151T3 (pl) 2011-08-31
KR20090104145A (ko) 2009-10-05
CY1116327T1 (el) 2017-02-08
CN102887903A (zh) 2013-01-23
TW200540177A (en) 2005-12-16
US20160250205A1 (en) 2016-09-01
US10407434B2 (en) 2019-09-10
PL2316837T3 (pl) 2018-07-31
EP2305683B8 (en) 2015-03-04
CA2557845A1 (en) 2005-10-20
IL213891A0 (en) 2011-07-31
MX363228B (es) 2019-03-15
HRP20160223T1 (hr) 2016-03-25
US20070179169A1 (en) 2007-08-02
DK2319846T3 (en) 2016-08-15
MX2020008878A (es) 2020-11-09
RS54598B1 (en) 2016-08-31
MY172063A (en) 2019-11-13
HRP20110425T4 (hr) 2020-11-27
CY1117841T1 (el) 2017-05-17
CN102127086B (zh) 2013-11-27
US20070117830A1 (en) 2007-05-24
HUE028233T2 (en) 2016-12-28
EP2426132A1 (en) 2012-03-07
CN102838607A (zh) 2012-12-26
KR101200700B1 (ko) 2012-11-13
KR100993911B1 (ko) 2010-11-11
US20110207762A1 (en) 2011-08-25
KR20140021716A (ko) 2014-02-20
CR8593A (es) 2007-07-19
ES2665287T3 (es) 2018-04-25
US20150265598A1 (en) 2015-09-24
MA28492B1 (fr) 2007-03-01
US20230159548A1 (en) 2023-05-25
DK1730151T4 (da) 2020-10-19
ATE501150T1 (de) 2011-03-15
EP2316837A1 (en) 2011-05-04
DK1730151T3 (da) 2011-06-20
KR20200000499A (ko) 2020-01-02
EP2311839A1 (en) 2011-04-20
EP2319846A1 (en) 2011-05-11
US7674798B2 (en) 2010-03-09
US20150265597A1 (en) 2015-09-24
ME01299B (me) 2011-10-31
FIU20070284U0 (fi) 2007-07-04
TW201231469A (en) 2012-08-01
PL2319846T3 (pl) 2016-12-30
NZ549430A (en) 2010-05-28
CA2557845C (en) 2013-10-01
JP2017125052A (ja) 2017-07-20
LT2316837T (lt) 2018-04-10
JP5378486B2 (ja) 2013-12-25
EP2319846B1 (en) 2016-05-04
JP2018184462A (ja) 2018-11-22
RS51693B2 (sr) 2021-02-26
US20160176889A1 (en) 2016-06-23
US20160176888A1 (en) 2016-06-23
ME03068B (me) 2019-01-20
TWI483944B (zh) 2015-05-11
ES2585576T3 (es) 2016-10-06
EP2314589B1 (en) 2022-12-28
EP2426132B1 (en) 2016-01-13
ES2938727T3 (es) 2023-04-14
KR101410141B1 (ko) 2014-06-25
BRPI0508758B1 (pt) 2018-10-09
FI7843U1 (fi) 2008-04-28
US20130005977A1 (en) 2013-01-03
CN101812065A (zh) 2010-08-25
AU2009200335B2 (en) 2011-07-28
JP2014139205A (ja) 2014-07-31
DK2426132T3 (en) 2016-04-04
EP1730151A1 (en) 2006-12-13
CR20110376A (es) 2011-09-19
CA2774121C (en) 2016-02-16
LT2314589T (lt) 2023-06-12
RS54941B1 (sr) 2016-11-30
US20160251363A1 (en) 2016-09-01
IL241117B (en) 2020-06-30
BRPI0508758B8 (pt) 2021-05-25
US20200087316A1 (en) 2020-03-19
WO2005097801A1 (en) 2005-10-20
US20070117831A1 (en) 2007-05-24
PT2426132E (pt) 2016-03-31
ES2362282T3 (es) 2011-06-30
JP2015187134A (ja) 2015-10-29
US20160251365A1 (en) 2016-09-01
AP2006003738A0 (en) 2006-10-31
US20190161492A1 (en) 2019-05-30
US20160250204A1 (en) 2016-09-01
DE602005026786D1 (de) 2011-04-21
US20180022754A1 (en) 2018-01-25
EP1730151B1 (en) 2011-03-09
HRP20180407T1 (hr) 2018-04-20
KR20150046393A (ko) 2015-04-29
US9073933B2 (en) 2015-07-07
US20210094963A1 (en) 2021-04-01
EP2305683A1 (en) 2011-04-06
JP4912294B2 (ja) 2012-04-11
JP2011157370A (ja) 2011-08-18
JP2012188439A (ja) 2012-10-04
KR20120106784A (ko) 2012-09-26
MY143205A (en) 2011-03-31
KR20110110377A (ko) 2011-10-06
US11384091B2 (en) 2022-07-12
MY154985A (en) 2015-08-28
JP5543991B2 (ja) 2014-07-09
US20160251364A1 (en) 2016-09-01
NO20064935L (no) 2006-12-18
PE20050880A1 (es) 2005-11-16
US20210198268A1 (en) 2021-07-01
IL178038A (en) 2015-10-29
ES2362282T5 (es) 2021-06-24
AR049012A1 (es) 2006-06-21
DK200700214U3 (da) 2008-02-08
BRPI0508758A (pt) 2007-08-28
ES2566363T3 (es) 2016-04-12
HRP20150358T1 (hr) 2015-05-08
US20200062772A1 (en) 2020-02-27
SI2319846T1 (sl) 2016-08-31
IL178038A0 (en) 2006-12-31
TWI365880B (en) 2012-06-11
SI2426132T1 (sl) 2016-04-29
HRP20160885T1 (hr) 2016-09-23
AU2005230826B2 (en) 2008-11-06
CN102838607B (zh) 2016-08-03
CA2774121A1 (en) 2005-10-20
US20160185790A1 (en) 2016-06-30
NZ602862A (en) 2014-01-31
US11236098B2 (en) 2022-02-01
KR20180088505A (ko) 2018-08-03
US20160264588A1 (en) 2016-09-15
TW201509943A (zh) 2015-03-16
DK2305683T3 (en) 2015-04-07
US20160175299A1 (en) 2016-06-23
SI2316837T1 (sl) 2018-05-31
CY1120171T1 (el) 2018-12-12
ECSP066953A (es) 2006-12-20
HK1098745A1 (en) 2007-07-27
ME02411B (me) 2016-09-20
CA2913355A1 (en) 2005-10-20
IL241117A0 (en) 2015-11-30
DK200700214U1 (da) 2007-11-23
EP2316837B1 (en) 2018-01-10
ES2535618T3 (es) 2015-05-13
AU2005230826C1 (en) 2014-10-16
CA2913355C (en) 2021-04-20
JP2012072162A (ja) 2012-04-12
RS53891B1 (en) 2015-08-31
KR20130020962A (ko) 2013-03-04
US10689389B2 (en) 2020-06-23
EA200601520A1 (ru) 2007-02-27
ME02482B (me) 2017-02-20
US7674799B2 (en) 2010-03-09
US20100152449A1 (en) 2010-06-17
HK1155728A1 (en) 2012-05-25
CN102127086A (zh) 2011-07-20
PL2426132T3 (pl) 2016-06-30
KR20100069719A (ko) 2010-06-24
KR20070022033A (ko) 2007-02-23
NZ601326A (en) 2013-10-25
NO337669B1 (no) 2016-05-30
EA013208B1 (ru) 2010-04-30
KR20120046309A (ko) 2012-05-09
KR100930730B1 (ko) 2009-12-09
US20160175300A1 (en) 2016-06-23
US20230365578A1 (en) 2023-11-16
HK1155729A1 (zh) 2012-05-25
US9777011B2 (en) 2017-10-03
PT1730151E (pt) 2011-06-01
US20070117829A1 (en) 2007-05-24
SG170736A1 (en) 2011-05-30
CN102887903B (zh) 2016-01-27
US7674800B2 (en) 2010-03-09
IL213890A (en) 2015-10-29
IL235298A (en) 2016-11-30
AP2232A (en) 2011-05-04
HRP20110425T1 (en) 2011-07-31
US20160185789A1 (en) 2016-06-30
PT2316837T (pt) 2018-04-02
SI1730151T1 (sl) 2011-06-30
US7129248B2 (en) 2006-10-31
US20060173029A1 (en) 2006-08-03
CY1117228T1 (el) 2017-04-05
EP2305683B1 (en) 2015-01-28
US20050222188A1 (en) 2005-10-06
EP2314589A1 (en) 2011-04-27
JP2007531756A (ja) 2007-11-08
RS51693B (en) 2011-10-31
PT2305683E (pt) 2015-05-18
US20160185788A1 (en) 2016-06-30
US10259819B2 (en) 2019-04-16
IL213889A (en) 2012-06-28
KR20140133615A (ko) 2014-11-19
JP6503392B2 (ja) 2019-04-17
AU2005230826A1 (en) 2005-10-20
US9522919B2 (en) 2016-12-20
SG10201406658VA (en) 2014-12-30
IL213890A0 (en) 2011-07-31
US20150258086A1 (en) 2015-09-17
US8822687B2 (en) 2014-09-02
JP5118223B2 (ja) 2013-01-16
IL213889A0 (en) 2011-07-31
SG170735A1 (en) 2011-05-30
DE202005021371U1 (de) 2007-10-25
AT9952U1 (de) 2008-06-15
EP1730151B2 (en) 2020-09-16
HUE036451T2 (hu) 2018-07-30
US20090227615A1 (en) 2009-09-10
PL2305683T3 (pl) 2015-07-31
US7683072B2 (en) 2010-03-23
SI1730151T2 (sl) 2021-03-31
AU2009200335A1 (en) 2009-02-26
US10696684B2 (en) 2020-06-30
ZA200607181B (en) 2007-11-28
IL213888A0 (en) 2011-07-31
PL1730151T5 (pl) 2023-09-18
CN101812065B (zh) 2012-03-28
CN1960994B (zh) 2012-09-05
CY1111487T1 (el) 2015-08-05
IL214050A0 (en) 2011-08-31
HUE029913T2 (en) 2017-04-28
DK2316837T3 (en) 2018-04-16
RS57000B1 (sr) 2018-05-31
EP1730151A4 (en) 2007-05-23
PT2319846T (pt) 2016-08-12
CN1960994A (zh) 2007-05-09

Similar Documents

Publication Publication Date Title
SI2305683T1 (sl) Farmacevtska odmerna oblika, ki obsega oksikodon hidroklorid in manj kot 25 ppm 14-hidroksikodeinona
EP1581188A4 (en) DOSAGE FORM WITH PHARMACEUTICAL SAFETY
EP1515674A4 (en) AGAINST MISUSE PROTECTED SOLID OPIOID DOSAGE FORM
AU2003302603A8 (en) Improved opioid pharmaceutical compositions
IL180706A0 (en) Pharmaceutical dosage forms including rasagiline
IL174690A0 (en) Enhanced drug delivery
GB0427455D0 (en) Dosage forms
EP1778252A4 (en) NON-CARDIOTOXIC PHARMACEUTICAL COMPOUNDS
GB0423964D0 (en) Dosage form
GB0512453D0 (en) Dosage unit
GB0424742D0 (en) Pharmaceutical compounds
GB0315019D0 (en) Dosage form
GB0313748D0 (en) Drug delivery compounds
GB0424994D0 (en) Dosage form
GB0411047D0 (en) Dosage form
GB0413234D0 (en) Drug delivery compounds
GB0411382D0 (en) Pharmaceutical compounds
GB0411383D0 (en) Pharmaceutical compounds
GB0408239D0 (en) Pharmaceutical compounds
GB0415082D0 (en) Pharmaceutical compounds
GB0415084D0 (en) Pharmaceutical compounds
GB0416373D0 (en) Pharmaceutical compounds
GB0423655D0 (en) Pharmaceutical compounds
GB0423684D0 (en) Pharmaceutical compounds
GB0412894D0 (en) Pharmaceutical compounds